23 Feb 2026 by admin in UncategorizedComments Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
11 Feb 2026 by admin in UncategorizedComments Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
09 Feb 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
